このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)

2017年7月26日 更新者:David Rizzieri, MD

Lenalidomide in Combination With Plerixafor in Patients With Previously Treated Chronic Lymphocytic Leukemia

In research studies, lenalidomide (also called Revlimid) has shown some response in chronic lymphocytic leukemia (CLL); however, responses are usually partial responses that occur after several months of taking the study drug. It is thought that by adding the drug plerixafor (also called Mozobil) responses may be improved and/or occur sooner.

The main purpose of this study is to determine the dose of plerixafor that is safe to use in combination with lenalidomide. The study will also look at the response rates of the combination of lenalidomide and plerixafor and the effect the study drugs have on CLL cells.

調査の概要

詳細な説明

The combination of lenalidomide and plerixafor will be evaluated in this single institution, open label clinical study of subjects with relapsed chronic lymphocytic leukemia (CLL). The overall design of the phase 1 study includes up to three treatment "stages."

Each subject will receive lenalidomide 5mg by mouth daily beginning on cycle 1 day 1. If tolerated, the dose will be increased by 2.5mg every 7 days to a maximum dose of 10mg by mouth daily (Stage 1). Once the subject is stably maintained on a daily dose of lenalidomide of 10mg daily and the white blood cell (WBC) count is <100.0 x 109 / L, and has been taking lenalidomide for at least 28 days, plerixafor will be added (Stage 2). In the dose escalation phase, 4 different doses of plerixafor in combination with lenalidomide will be studied in cohorts of 3 to 6 subjects each, following a standard "3 + 3" format:

  • Cohort 1: plerixafor 0.24 mg/kg subcutaneous (SC) daily thrice weekly (Mon, Wed, Fri)
  • Cohort 2: plerixafor 0.32 mg/kg SC daily thrice weekly (Mon, Wed, Fri)
  • Cohort 3: plerixafor 0.42 mg/kg SC daily thrice weekly (Mon, Wed, Fri)
  • Cohort 4: plerixafor 0.54 mg/kg SC daily thrice weekly (Mon, Wed, Fri) Plerixafor will be administered for 3 weeks of each cycle (days 1, 3, 5, 8, 10, 12, 15, 17, and 19) followed by a 1 week rest period. Lenalidomide dosing will be continuous.

An interim assessment of response will be performed after 4 cycles of combination therapy:

  • Subjects achieving a complete response (CR) by National Cancer Institute (NCI)-96 criteria will continue lenalidomide monotherapy (plerixafor is discontinued) until disease progression.
  • Subjects achieving a partial response (PR) will continue both lenalidomide and plerixafor. Additionally, rituximab 375mg/m2 will be added on day 1 of each subsequent cycle beginning with cycle 5, day 1 of combination therapy. (Stage 3). Treatment with the combination of lenalidomide and plerixafor will continue for a maximum of 12 cycles of combination therapy. Subjects may receive up to 8 doses of rituximab concurrent with lenalidomide and plerixafor on day 1 of each cycle. Subjects will then continue single agent lenalidomide until disease progression.
  • Subjects with stable disease may continue lenalidomide and plerixafor at the discretion of the investigator and the subject. Rituximab 375 mg/m2 will be added on day 1 of each subsequent cycle. Treatment, dose, schedule, and duration are the same as for subjects achieving a PR.

研究の種類

介入

入学 (実際)

21

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • North Carolina
      • Durham、North Carolina、アメリカ、27710
        • Duke University Medical Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Histologically confirmed diagnosis of chronic lymphocytic leukemia (CLL) or Small lymphocytic lymphoma (SLL) as established by the National Cancer Institute (NCI) Working Group Response Criteria (NCI 96 Criteria).
  • Received one or more prior therapies for CLL.
  • Subjects must have symptomatic disease requiring therapy as defined by the protocol.
  • >/= 4 weeks from prior cancer therapy.
  • Eastern Cooperative Oncology Group (ECOG) performance status of </= 2.
  • All study subjects must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®.

Exclusion Criteria:

  • Prolymphocytic leukemia (PLL).
  • Richter's (large cell) transformation.
  • Prior allogeneic transplant within 12 months or prior allogeneic transplant > 12 months currently receiving immunosuppressants.
  • Active autoimmune hemolytic anemia.
  • Central nervous system (CNS) involvement.
  • Chronic enteral corticosteroids > 10mg prednisone or equivalent.
  • Evidence of laboratory tumor lysis syndrome (TLS) by Cairo-Bishop Definition of Tumor Lysis Syndrome
  • Use of any other experimental drug or therapy within 28 days of baseline
  • Major surgery within 28 days of baseline.
  • Known hypersensitivity to thalidomide.
  • The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
  • Any prior use of lenalidomide.
  • Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV).

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Lenalidomide + Plerixafor+ Rituximab
  1. Lenalidomide 5mg by mouth (PO) daily beginning cycle 1 day 1.
  2. Stage 1: increase by 2.5mg every 7 days to a maximum dose of 10mg.
  3. Stage 2: plerixafor will be added after 28 days of 10mg dose maintenance and white blood cell count (WBC) <100.0 x 109 / L.
  4. Dose cohorts of escalating subcutaneous (SC) thrice weekly plerixafor with continuous 10mg lenalidomide:

    • Cohort 1: 0.24 mg/kg
    • Cohort 2: 0.32 mg/kg
    • Cohort 3: 0.42 mg/kg
    • Cohort 4: 0.54 mg/kg
  5. Stage 3: Rituximab 375mg/m2 will be added on day 1 of cycles 5-12, day 1 of combination therapy for subjects with PR.
  6. Subjects will then continue single agent lenalidomide until disease progression.
  1. Lenalidomide 5mg by mouth (PO) daily beginning cycle 1 day 1.
  2. Stage 1: increase by 2.5mg every 7 days to a maximum dose of 10mg.
  3. Stage 2: plerixafor will be added after 28 days of 10mg dose maintenance and white blood cell count (WBC) <100.0 x 109 / L.
  4. Dose cohorts of escalating subcutaneous (SC) thrice weekly plerixafor with continuous 10mg lenalidomide:

    • Cohort 1: 0.24 mg/kg
    • Cohort 2: 0.32 mg/kg
    • Cohort 3: 0.42 mg/kg
    • Cohort 4: 0.54 mg/kg
  5. Stage 3: Rituximab 375mg/m2 will be added on day 1 of cycles 5-12, day 1 of combination therapy for subjects with PR.
  6. Subjects will then continue single agent lenalidomide until disease progression.
他の名前:
  • レブラミド
  • リツキサン
  • モゾビル

この研究は何を測定していますか?

主要な結果の測定

結果測定
時間枠
Maximum Tolerated Dose
時間枠:4-16 months
4-16 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Overall Response (Complete Response/Partial Response)
時間枠:at the end of 4 months of combination treatment and at 2 months after completion of therapy

NCI 96 Response Criteria

CR (Complete Response):

Lymphadenopathy = none > 1.5cm Hepatomegaly = none Splenomegaly = none Blood lymphocytes = <4000 per microliter Marrow = normocellular, <30% lymphocytes, no B-lymphoid nodules. Platelet count = >100,000 per microliter Hemoglobin = >11.0 grams per deciliter Neutrophils = >1500 per microliter

PR (Partial Response):

Lymphadenopathy = Decrease >/= 50% Hepatomegaly = Decrease >/= 50% Splenomegaly = Decrease >/= 50% Blood lymphocytes = Decrease >/= 50% from baseline Marrow = 50% reduction in marrow infiltrate or B-lymphoid nodules. Platelet count = >100,000 per microliter or increase >/= 50% over baseline Hemoglobin = >11.0 grams per deciliter or increase >/= 50% over baseline Neutrophils = >1500 per microliter or increase >/= 50% over baseline

at the end of 4 months of combination treatment and at 2 months after completion of therapy
Progression-free Survival (PFS)
時間枠:time from day 1 of treatment to disease progression, death, or 2 years, whichever comes first
time from day 1 of treatment to disease progression, death, or 2 years, whichever comes first
Overall Survival (OS)
時間枠:the time from day 1 of treatment to death or 2 years, whichever comes first
the time from day 1 of treatment to death or 2 years, whichever comes first
Reduction in Severity of B Symptoms
時間枠:at the end of stage 1 (lenalidomide alone), at the end of stage 2 (4 months of combination), and at 2 months post-completion of therapy
Reduction in the severity of the following B symptoms will be assessed: fever ≥ 101F, chills, night sweats, and anorexia with weight loss.
at the end of stage 1 (lenalidomide alone), at the end of stage 2 (4 months of combination), and at 2 months post-completion of therapy
Reduction in the Frequency of Blood and Platelet Transfusions
時間枠:4 weeks prior to therapy and in the 4 weeks following the completion of therapy
The change in number of transfusions from pre- to post-treatment will be calculated and summarized across all patients by giving the minimum, the 25th, 50th (median) and the 75th percentile and the maximum.
4 weeks prior to therapy and in the 4 weeks following the completion of therapy

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2012年1月1日

一次修了 (実際)

2014年3月1日

研究の完了 (実際)

2015年3月1日

試験登録日

最初に提出

2011年6月12日

QC基準を満たした最初の提出物

2011年6月13日

最初の投稿 (見積もり)

2011年6月14日

学習記録の更新

投稿された最後の更新 (実際)

2018年2月5日

QC基準を満たした最後の更新が送信されました

2017年7月26日

最終確認日

2017年7月1日

詳しくは

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する